33620 Results

People

  1. Ladanyi
    Ladanyi
  2. Giralt
    Giralt
  3. Motzer
    Motzer
  4. Reuter
    Reuter
  5. Perales
    Perales
  6. Scher
    Scher
  7. Zelenetz
    Zelenetz
  8. Berger
    Berger
  9. Al-Ahmadie
    Al-Ahmadie
  10. O'Reilly
    O'Reilly

Groups

  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)
  7. Department of Pathology and Laboratory Medicine (5172)
  8. Surgery (4871)
  9. Sloan Kettering Institute Faculty (3826)
  10. Sloan Kettering Institute Postdocs (3612)
  1. "Meeting abstract"
Formats
  1. Meeting Abstract (33620)
Groups
  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)

More Groups

People
  1. Marc Ladanyi (641)
  2. Sergio Giralt (632)
  3. Robert Motzer (574)
  4. Victor Reuter (568)
  5. Miguel-Angel Perales (482)
  6. Howard Scher (463)

More People

Years
  1. 2025 (295)
  2. 2024 (1694)
  3. 2023 (1954)
  4. 2022 (2196)
  5. 2021 (1731)
  6. 2020 (1901)

More Years

Publications
  1. Journal of Clinical Oncology (6252)
  2. Blood (3939)
  3. Laboratory Investigation (1846)
  4. Cancer Research (1822)
  5. International Journal of Radiation Oncology, Biology, Physics (1643)
  6. Modern Pathology (1494)

More Publications

Publishers
  1. American Society of Clinical Oncology (6251)
  2. Elsevier Inc. (4694)
  3. American Society of Hematology (3939)
  4. American Association for Cancer Research (3045)
  5. Nature Publishing Group (2151)
  6. Oxford University Press (2096)

More Publishers

Results (33620)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Association of intraoperative opioids with improved recurrence-free survival in triple-negative breast cancer
    Meeting Abstract

    Montagna, G.; Hannum, M. L.; Tan, K. S.; Plitas, G.; McCormick, P. J.; Fischer, G. W.; Morrow, M.; Mincer, J. S.
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Effects of radiation therapy on clonal hematopoiesis
    Meeting Abstract

    Modlin, L. A.; Wijetunga, N. A.; Patel, M.; Gao, T.; Ptashkin, R.; Sullivan, M. R.; Kelly, D. W.; Caltabellotta, N.; Solit, D. B.; Berger, M. F.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • The correlation between clinical benefit and financial cost of cancer drugs
    Meeting Abstract

    Mitchell, A. P.; Tabatabai, S.; Dey, P.; Ohn, J.; Curry, M. A.; Bach, P.
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Real-world analysis of clinical and economic impact of 21-gene recurrence score (RS) testing in early-stage breast cancer (ESBC) in Ireland
    Meeting Abstract

    McSorley, L. M.; Al Rahbi, F.; Tharmabala, M.; Evoy, D.; Geraghty, J. G.; Prichard, R.; Rothwell, J.; McCartan, D.; McDermott, E.; Keane, M. M.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • The association between drug industry payments and NCCN guideline panel membership
    Meeting Abstract

    Mitchell, A. P.; Mishra, A. A.; Dey, P.; Curry, M. A.; Trivedi, N. A.; Haddadin, M.; Rahman, M.; Winn, A. N.; Dusetzina, S.; Bach, P.
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Vorasidenib (VOR; AG-881), an inhibitor of mutant IDH1 and IDH2, in patients (pts) with recurrent/progressive glioma: Updated results from the phase I non-enhancing glioma population
    Meeting Abstract

    Mellinghoff, I. K.; Peters, K. B.; Cloughesy, T. F.; Burris, H. A. 3rd; Maher, E. A.; Janku, F.; Cote, G. M.; De La Fuente, M. I.; Clarke, J. L.; Kha, L.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Survival outcomes among older adults (OA) receiving second-line therapy for metastatic CRC (mCRC): 5,289 patients (pts) from the ARCAD Clinical Trials Program
    Meeting Abstract

    McCleary, N. J.; Harmsen, W. S.; VanCutsem, E.; Sobrero, A. F.; Goldberg, R. M.; Tabernero, J.; Seymour, M.; Saltz, L. B.; Giantonio, B. J.; Dirk, A.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Results of a phase II trial of intense androgen deprivation therapy prior to radical prostatectomy (RP) in men with high-risk localized prostate cancer (PC)
    Meeting Abstract

    McKay, R. R.; Xie, W.; Fennessy, F. M.; Zhang, Z.; Lis, R.; Rathkopf, D. E.; Laudone, V. P.; Bubley, G.; Einstein, D. J.; Chang, P.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Pembrolizumab with trastuzumab and chemotherapy (PTC) in HER2-positive metastatic esophagogastric cancer (mEG): Plasma and tumor-based biomarker analysis
    Meeting Abstract

    Maron, S. B.; Chatila, W. K.; Millang, B. M.; Sabwa, S.; Chou, J. F.; Ling, L.; Nagy, R.; Simmons, M.; Do, R. K. G.; Paroder, V.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Impact of premature venetoclax (Ven) discontinuation/interruption on outcomes in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Phase III MURANO study results
    Meeting Abstract

    Mato, A. R.; Sharman, J. P.; Biondo, J.; Wu, M.; Mun, Y.; Kim, S. Y.; Humphrey, K.; Boyer, M.; Zhu, Q.; Seymour, J. F.
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save